Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

The ALERT-B questionnaire: A screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer.

Farnell DJJ, Staffurth J, Sivell S, Ahmedzai S, Andreyev J, Green J, Sanders DS, Ferguson CJ, Pickett S, Muls A, O'Shea R, Campbell SH, Taylor SE, Nelson A.

Clin Transl Radiat Oncol. 2020 Feb 4;21:98-103. doi: 10.1016/j.ctro.2020.02.002. eCollection 2020 Mar.

2.

Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.

Murray J, Gulliford S, Griffin C, Wilkins A, Syndikus I, Staffurth J, Panades M, Scrase C, Parker C, Khoo V, Dean J, Mayles H, Mayles P, Thomas S, Naismith O, Mossop H, Cruickshank C, Hall E, Dearnaley D; CHHiP Investigators.

Clin Transl Radiat Oncol. 2019 Dec 31;21:77-84. doi: 10.1016/j.ctro.2019.12.006. eCollection 2020 Mar.

3.

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.

Bryant RJ, Oxley J, Young GJ, Lane JA, Metcalfe C, Davis M, Turner EL, Martin RM, Goepel JR, Varma M, Griffiths DF, Grigor K, Mayer N, Warren AY, Bhattarai S, Dormer J, Mason M, Staffurth J, Walsh E, Rosario DJ, Catto JWF, Neal DE, Donovan JL, Hamdy FC; ProtecT Study Group.

BJU Int. 2020 Apr;125(4):506-514. doi: 10.1111/bju.14987. Epub 2020 Feb 12.

PMID:
31900963
4.

Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.

Clark E, Morton M, Sharma S, Fisher H, Howel D, Walker J, Wood R, Hancock H, Maier R, Marshall J, Bahl A, Crabb S, Jain S, Pedley I, Jones R, Staffurth J, Heer R.

BMJ Open. 2019 Dec 18;9(12):e034708. doi: 10.1136/bmjopen-2019-034708.

5.

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC; ProtecT Study Group.

Eur Urol. 2020 Mar;77(3):320-330. doi: 10.1016/j.eururo.2019.10.030. Epub 2019 Nov 24.

6.

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.

Murray J, Griffin C, Gulliford S, Syndikus I, Staffurth J, Panades M, Scrase C, Parker C, Khoo V, Dean J, Mayles H, Mayles P, Thomas S, Naismith O, Baker A, Mossop H, Cruickshank C, Hall E, Dearnaley D; CHHiP Investigators.

Radiother Oncol. 2020 Jan;142:62-71. doi: 10.1016/j.radonc.2019.10.017. Epub 2019 Nov 22.

7.

The Trigger Project: The Challenge of Introducing Electronic Patient-Reported Outcome Measures Into a Radiotherapy Service.

Macnair A, Sharkey A, Le Calvez K, Walters R, Smith L, Nelson A, Staffurth J, Williams M, Bloomfield D, Maher J.

Clin Oncol (R Coll Radiol). 2020 Feb;32(2):e76-e79. doi: 10.1016/j.clon.2019.09.044. Epub 2019 Sep 28. No abstract available.

PMID:
31575427
8.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators.

Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17.

9.

Evaluating the application of Pareto navigation guided automated radiotherapy treatment planning to prostate cancer.

Wheeler PA, Chu M, Holmes R, Woodley OW, Jones CS, Maggs R, Staffurth J, Palaniappan N, Spezi E, Lewis DG, Campbell S, Fitzgibbon J, Millin AE.

Radiother Oncol. 2019 Dec;141:220-226. doi: 10.1016/j.radonc.2019.08.001. Epub 2019 Sep 13.

10.

The Preferences of Patients With Cancer Regarding Apps to Help Meet Their Illness-Related Information Needs: Qualitative Interview Study.

Richards R, Kinnersley P, Brain K, Staffurth J, Wood F.

JMIR Mhealth Uhealth. 2019 Jul 31;7(7):e14187. doi: 10.2196/14187.

11.

Assessing radiomic feature robustness to interpolation in 18F-FDG PET imaging.

Whybra P, Parkinson C, Foley K, Staffurth J, Spezi E.

Sci Rep. 2019 Jul 4;9(1):9649. doi: 10.1038/s41598-019-46030-0.

12.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ.

Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14.

13.

Interim 18F-FDG Positron Emission Tomography/Computed Tomography During Chemoradiotherapy in the Management of Cancer Patients: a Response.

Hargreaves S, Johnstone E, Parkinson C, Rackley T, Spezi E, Staffurth J, Evans M.

Clin Oncol (R Coll Radiol). 2019 Sep;31(9):669-670. doi: 10.1016/j.clon.2019.05.005. Epub 2019 May 29. No abstract available.

PMID:
31151841
14.

Machine-learned target volume delineation of 18F-FDG PET images after one cycle of induction chemotherapy.

Parkinson C, Evans M, Guerrero-Urbano T, Michaelidou A, Pike L, Barrington S, Jayaprakasam V, Rackley T, Palaniappan N, Staffurth J, Marshall C, Spezi E.

Phys Med. 2019 May;61:85-93. doi: 10.1016/j.ejmp.2019.04.020. Epub 2019 May 3.

PMID:
31151585
15.

Impact of deviations in target volume delineation - Time for a new RTQA approach?

Cox S, Cleves A, Clementel E, Miles E, Staffurth J, Gwynne S.

Radiother Oncol. 2019 Aug;137:1-8. doi: 10.1016/j.radonc.2019.04.012. Epub 2019 Apr 28. Review.

PMID:
31039468
16.

A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy.

Jadon R, Higgins E, Hanna L, Evans M, Coles B, Staffurth J.

Radiat Oncol. 2019 Apr 3;14(1):57. doi: 10.1186/s13014-019-1262-8.

17.

Methods of assessing late radiotherapy effects on bowel function.

Nelson A, Mann M, Staffurth J.

Curr Opin Support Palliat Care. 2019 Jun;13(2):134-141. doi: 10.1097/SPC.0000000000000422. Review.

PMID:
30925532
18.

Driving developments in UK oesophageal radiotherapy through the SCOPE trials.

Gwynne S, Higgins E, Poon King A, Radhakrishna G, Wills L, Mukherjee S, Hawkins M, Jones G, Staffurth J, Crosby T.

Radiat Oncol. 2019 Feb 4;14(1):26. doi: 10.1186/s13014-019-1225-0.

19.

Use of Mobile Devices to Help Cancer Patients Meet Their Information Needs in Non-Inpatient Settings: Systematic Review.

Richards R, Kinnersley P, Brain K, McCutchan G, Staffurth J, Wood F.

JMIR Mhealth Uhealth. 2018 Dec 14;6(12):e10026. doi: 10.2196/10026. Review.

20.

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).

Dearnaley D, Griffin CL, Lewis R, Mayles P, Mayles H, Naismith OF, Harris V, Scrase CD, Staffurth J, Syndikus I, Zarkar A, Ford DR, Rimmer YL, Horan G, Khoo V, Frew J, Venkitaraman R, Hall E.

Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):605-617. doi: 10.1016/j.ijrobp.2018.10.003. Epub 2018 Dec 6.

21.

External validation of a prognostic model incorporating quantitative PET image features in oesophageal cancer.

Foley KG, Shi Z, Whybra P, Kalendralis P, Larue R, Berbee M, Sosef MN, Parkinson C, Staffurth J, Crosby TDL, Roberts SA, Dekker A, Wee L, Spezi E.

Radiother Oncol. 2019 Apr;133:205-212. doi: 10.1016/j.radonc.2018.10.033. Epub 2018 Nov 10.

PMID:
30424894
22.

Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.

Payne H, McMenemin R, Bahl A, Greene D, Staffurth J.

Int J Clin Pract. 2019 Sep;73(9):1-6. doi: 10.1111/ijcp.13292. Epub 2018 Dec 4.

PMID:
30414348
23.

The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D, Choudhury A, Graham J, Ferguson C, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Rimmer Y, Scrase C, Staffurth J, Stockdale A, Cruickshank C, Griffin C, Hall E; CHHiP Investigators.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1179-1189. doi: 10.1016/j.ijrobp.2018.01.016. Epub 2018 Jan 9.

24.

National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting.

Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A, Barrett T, Giganti F, Graham J, Haslam P, Johnston EW, Kastner C, Kirkham APS, Lipton A, McNeill A, Moniz L, Moore CM, Nabi G, Padhani AR, Parker C, Patel A, Pursey J, Richenberg J, Staffurth J, van der Meulen J, Walls D, Punwani S.

BJU Int. 2018 Jul;122(1):13-25. doi: 10.1111/bju.14361. Epub 2018 Jun 5.

25.

Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods.

Parkinson C, Foley K, Whybra P, Hills R, Roberts A, Marshall C, Staffurth J, Spezi E.

EJNMMI Res. 2018 Apr 11;8(1):29. doi: 10.1186/s13550-018-0379-3.

26.

Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.

Wills L, Maggs R, Lewis G, Jones G, Nixon L, Staffurth J, Crosby T; SCOPE 1 trial management group and collaborators.

Radiat Oncol. 2017 Nov 15;12(1):179. doi: 10.1186/s13014-017-0916-7.

27.

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.

Hurt CN, Falk S, Crosby T, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T, Mukherjee S.

Br J Cancer. 2017 May 9;116(10):1264-1270. doi: 10.1038/bjc.2017.95. Epub 2017 Apr 4.

28.

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.

Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G, Mukherjee S.

Br J Cancer. 2017 Mar 14;116(6):709-716. doi: 10.1038/bjc.2017.21. Epub 2017 Feb 14.

29.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

30.

Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project.

Taylor S, Demeyin W, Muls A, Ferguson C, Farnell DJ, Cohen D, Andreyev J, Green J, Smith L, Ahmedzai S, Pickett S, Nelson A, Staffurth J.

BMJ Open. 2016 Oct 3;6(10):e011773. doi: 10.1136/bmjopen-2016-011773.

31.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group.

N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.

32.

Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial.

Fokas E, Spezi E, Patel N, Hurt C, Nixon L, Chu KY, Staffurth J, Abrams R, Mukherjee S.

Radiother Oncol. 2016 Aug;120(2):212-6. doi: 10.1016/j.radonc.2016.07.002. Epub 2016 Aug 3.

33.

TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.

James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L.

Health Technol Assess. 2016 Jul;20(53):1-288. doi: 10.3310/hta20530.

34.

Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.

Mason MD, Moore R, Jones G, Lewis G, Donovan JL, Neal DE, Hamdy FC, Lane JA, Staffurth JN; ProtecT Study Group.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e92-e100. doi: 10.1016/j.clon.2016.05.011. Epub 2016 Jul 12.

PMID:
27425582
35.

The Three-item ALERT-B Questionnaire Provides a Validated Screening Tool to Detect Chronic Gastrointestinal Symptoms after Pelvic Radiotherapy in Cancer Survivors.

Taylor S, Byrne A, Adams R, Turner J, Hanna L, Staffurth J, Farnell D, Sivell S, Nelson A, Green J.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):e139-47. doi: 10.1016/j.clon.2016.06.004. Epub 2016 Jun 29.

36.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators.

Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Erratum in: Lancet Oncol. 2016 Aug;17 (8):e321.

37.

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).

Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown JE, Chakraborti P, Hussain SA, Russell JM, Billingham LJ, James ND.

BJU Int. 2017 Apr;119(4):522-529. doi: 10.1111/bju.13549. Epub 2016 Jul 10.

38.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

39.

Prospective review of radiotherapy trials through implementation of standardized multicentre workflow and IT infrastructure.

Gwynne S, Jones G, Maggs R, Eaton D, Miles E, Staffurth J, Nixon L, Ray R, Lewis G, Crosby T, Spezi E.

Br J Radiol. 2016 Aug;89(1064):20160020. doi: 10.1259/bjr.20160020. Epub 2016 Jun 1.

40.

High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice.

Tanguay JS, Catlow C, Smith C, Barber J, Staffurth J, Kumar S, Palaniappan N, Button M, Mason MD.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):611. doi: 10.1016/j.clon.2016.03.006. Epub 2016 May 4. No abstract available.

PMID:
27131755
41.

The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial.

Carrington R, Spezi E, Gwynne S, Dutton P, Hurt C, Staffurth J, Crosby T.

Radiat Oncol. 2016 Feb 6;11:19. doi: 10.1186/s13014-016-0594-x.

42.

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Hussain S, Russell M, Billingham LJ.

JAMA Oncol. 2016 Apr;2(4):493-9. doi: 10.1001/jamaoncol.2015.5570.

43.

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.

Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.

44.

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation.

Carrington R, Staffurth J, Warren S, Partridge M, Hurt C, Spezi E, Gwynne S, Hawkins MA, Crosby T.

Radiat Oncol. 2015 Nov 19;10:236. doi: 10.1186/s13014-015-0537-y.

45.

Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.

Hurt CN, Mukherjee S, Bridgewater J, Falk S, Crosby T, McDonald A, Joseph G, Staffurth J, Abrams RA, Blazeby JM, Bridges S, Dutton P, Griffiths G, Maughan T, Johnson C.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):810-8. doi: 10.1016/j.ijrobp.2015.08.026. Epub 2015 Aug 24.

46.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E.

Lancet Oncol. 2015 Dec;16(16):1605-16. doi: 10.1016/S1470-2045(15)00280-6. Epub 2015 Oct 28.

47.

What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?

Davies RS, Smith C, Button MR, Tanguay J, Barber J, Palaniappan N, Staffurth J, Lester JF.

Anticancer Res. 2015 Oct;35(10):5615-21.

PMID:
26408734
48.

Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial.

Fokas E, Clifford C, Spezi E, Joseph G, Branagan J, Hurt C, Nixon L, Abrams R, Staffurth J, Mukherjee S.

Radiother Oncol. 2015 Dec;117(3):432-7. doi: 10.1016/j.radonc.2015.08.026. Epub 2015 Aug 29.

PMID:
26328939
49.

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.

Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T.

Br J Cancer. 2015 Aug 11;113(4):603-10. doi: 10.1038/bjc.2015.258. Epub 2015 Jul 23.

50.

Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.

Harris VA, Staffurth J, Naismith O, Esmail A, Gulliford S, Khoo V, Lewis R, Littler J, McNair H, Sadoyze A, Scrase C, Sohaib A, Syndikus I, Zarkar A, Hall E, Dearnaley D; PIVOTAL Trialists.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):874-83. doi: 10.1016/j.ijrobp.2015.03.021. Epub 2015 Mar 30.

PMID:
26104940

Supplemental Content

Loading ...
Support Center